Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of AHB-171 injection in chronic hepatitis B
CTR20261972Phase 2Active
- Sponsor
- HaoBo Medicine
- Start
- Jun 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-171 in Chronic Hepatitis B (CHB), sponsored by HaoBo Medicine. Started Jun 2026; status: active.
02
Drugs
AHB-171
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20261972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261972.